

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 05-1044-B5; EX04-044C-US)

In the Application of:	j
Michael R. Costa et al.	)
International App. No.: PCT/US04/19533	) Examiner: To Be Assigned )
U.S. Serial No.: 10/556,937	) Group Art Unit: To Be Assigned
International Filing Date: June 18, 2004	) Confirmation No. 6980
For: MARKs As Modifiers of the PTEN Pathway and Method of Use	) } )

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following reference of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copy of the reference cited below is enclosed. The reference is also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed reference may be material to the Examiner's consideration of the presently pending claims. However, the reference has not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed reference has effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

#### **Other Documents**

1. Drewes G. et al., MARK, a Novel Family of Protein Kinases the phosphorylate Microtubule-Associated Proteins and Trigger Microtubule Distruction; Cell, April 18, 1997, Vol. 89, pages 297-308.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Date: November 15, 2000

By:

Anita J. Terpstra Reg. No. 47,132

McDonnell, Boehnen Hulbert & Berghoff

300 South Wacker Drive Chicago, IL 60606

Respectfully submitted,

PTO/SB/08b (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO			Complete if Known			
				Application Number	10/556,937	
INFORMATION DISCLOSURE			URE	Filing Date	November 10, 2005	
ST	ATEMENT BY AF	PPLIC	ANT	First Named Inventor	Michael Costa	
(Use as many sheets as necessary)		Art Unit	N/A			
		Examiner Name	N/A			
Sheet	11	of	2	Attorney Docket Number	05-1044-B	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
		Drewes G. Et al. MARK, a Novel Family of Protein Kinases the phosphorylate Microtubule-Assocaited Proteins and Trigger Microtubule Districution. Cell, 18 April 1997, Vol. 89, pgs. 297-308.		
Examiner		Date		

Examiner Signature	Date Considered	
· · · · · · · · · · · · · · · · · · ·		

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINE X: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments are the application in the complete this form and/or suppositions for reducing this hurden should be cost to the Chief Information Officer LLS Patents. on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





**PATENT** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 05-1044-B5; EX04-044C-US)

In the Application of:	)
Michael R. Costa et al.	
International App. No.: PCT/US04/19533	) Examiner: To Be Assigned )
U.S. Serial No.: 10/556,937	) Group Art Unit: To Be Assigned
International Filing Date: June 18, 2004	) Confirmation No. 6980
For: MARKs As Modifiers of the PTEN Pathway and Method of Use	)

### TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

- 1. We are transmitting herewith the attached:
  - a) Information Disclosure Statement;
  - b) PTO Form-1449;
  - c) Copy of cited reference; and
  - d) Return receipt postcard.
- 2. With respect to fees:
  - a) No fee is believed to be due at this time.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited via first class mail with the United States Post Office, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 152006.

Respectfully submitted,

Date: November 15, 2006

Amita J. Terpstra

Registration No. 47,132





# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 05-1044-B5; EX04-044C-US)

In the Application of:	)
Michael R. Costa et al.	,
International App. No.: PCT/US04/19533	) Examiner: To Be Assigned )
U.S. Serial No.: 10/556,937	) Group Art Unit: To Be Assigned
International Filing Date: June 18, 2004	) Confirmation No. 6980
For: MARKs As Modifiers of the PTEN Pathway and Method of Use	) )

#### TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

- 1. We are transmitting herewith the attached:
  - a) Information Disclosure Statement;
  - b) PTO Form-1449;
  - c) Copy of cited reference; and
  - d) Return receipt postcard.
- 2. With respect to fees:
  - a) No fee is believed to be due at this time.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

Respectfully submitted,

Date: November 15, 2006

Amita J. Terpstra

Registration No. 47,132